Skip to main content
. 2020 Sep 2;11:550205. doi: 10.3389/fphar.2020.550205

Table 4.

Baseline characteristics of virological failures (n = 76).

Parameter Relapsed (n = 20) Nonresponder (n = 56) P value
Age (y), M ± SD 61.2 ± 10.2 57 ± 18.6
Male, n (%) 7 (35) 23 (41)
BMI >30, n (%) 6 (30) 16 (29) 0.01
Treatment experienced, n (%) 13 (65) 33 (59)
Cirrhosis, n (%) 17 (85) 27 (48)
Treatment arm 0.01
SOF/DCV, n (%) 14 (70) 40 (71.4)
SOF/VEL, n (%) 6 (30) 16 (28.6)
Laboratory data
HB (g/dl) M ± SD 13.1 ± 1.6 13.0 ± 2
WBCs (×109/L) M ± SD 7.6 ± 2.6 6.8 ± 1.8
PLT (×109/L) M ± SD 203 ± 77 211 ± 83
AST (ULN: 40 U/L) M ± SD 69.9 ± 34.2 68.9 ± 36.3
ALT (ULN: 40 U/L) M ± SD 87.32 ± 68.4 88.2 ± 68.5
Albumin (g/L) M ± SD 39.6 ± 3.5 39.8 ± 6.3
Creatinine (mg/dl) M ± SD 99.03 ± 25 100 ± 26
INR M ± SD 1.2 ± 0.1 1.1 ± 0.1
TBR (μmol/L) M ± SD 9.44 ± 3.4 11.29 ± 5.6
HCV PCR log10 6.2 ± 0.3 6.4 ± 0.9 0.02
Comorbidities
Diabetes, n (%) 13 (65) 10 (18)
Obesity, n (%) 13 (65) 10 (18)
Hypertension, n (%) 20 (100) 38 (67)
HBsAg, n (%) 1 (5) 0 (0.0)
Risk factors
Blood transfusion, n (%) 19 (95) 27 (48)
Surgery, n (%) 12 (60) 10 (18)
Tobacco smoking, n (%) 19 (95) 13 (13)

Bold values represent statistical significance.